1. Medtech Insight
  2. >>Archive

TriCardia in IP (intellectual property) & cardiovascular device venture:

Early-stage venture capital fund St Paul Venture Capital has joined with TriCardia to form a company that aims to identify promising product concepts that can form the basis of marketable intellectual property or early-stage cardiovascular device companies. TriCardia Venture will seek to exploit the access to entrepreneurs and experts in the device field enjoyed by TriCardia, while St Paul will provide the pre-seed capital that will enable completion of research or other proof of concept work. Robert Van Tassel of TriCardia and Robert Schwartz of St Paul Venture Capital, are among the principals. TriCardia was set up to consult with medical device companies in the development of new products and has an extensive network of consultants.

Early-stage venture capital fund St Paul Venture Capital has joined with TriCardia to form a company that aims to identify promising product concepts that can form the basis of marketable intellectual property or early-stage cardiovascular device companies. TriCardia Venture will seek to exploit the access to entrepreneurs and experts in the device field enjoyed by TriCardia, while St Paul will provide the pre-seed capital that will enable completion of research or other proof of concept work. Robert Van Tassel of TriCardia and Robert Schwartz of St Paul Venture Capital, are among the principals. TriCardia was set up to consult with medical device companies in the development of new products and has an extensive network of consultants.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Quest Diagnostics Minimizes China Tariff Risk With Less Than 1% Supply Chain Exposure

 
• By Shubham Singh

Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.

Abbott Launches Next-Gen Delivery System For Proclaim DRG Neurostim

 
• By Shubham Singh

Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.